NMN for Non-Alcoholic Steatohepatitis: What the Evidence Actually Shows
What is Non-Alcoholic Steatohepatitis?
NASH is the inflammatory progression of fatty liver disease, with hepatocyte damage and fibrosis. Untreated, it can progress to cirrhosis and liver cancer.
NMN relevance: the published evidence
NR (a related precursor) has been tested in small NAFLD/NASH human studies with mixed liver-fat results. No NMN trial in biopsy-confirmed NASH has been completed. Resmetirom, weight loss and metabolic control are the evidence-based interventions.
Questions to ask before supplementing
No dose validated in NASH.
Contraindications and red flags
Coordinate with hepatology; do not delay biopsy-driven care.
Bottom line for Malaysian patients
NMN is not registered with NPRA as a treatment for any specific condition; it is sold as a general health supplement. If you have non-alcoholic steatohepatitis, use this page as a question list for a registered medical practitioner before adding NMN to existing therapy. Read our safety guide for full red-flag context.
Related conditions
- Non-Alcoholic Fatty Liver Disease - NAFLD is fat accumulation in the liver unrelated to alcohol, often tied to obesity and insulin resis...
- Obesity - Obesity is excess body fat that raises the risk of diabetes, heart disease, joint problems and certa...
- Type 2 Diabetes - Type 2 diabetes is a chronic condition where the body becomes resistant to insulin and blood glucose...
- Metabolic Syndrome - Metabolic syndrome is a cluster of conditions including central obesity, high blood pressure, dyslip...